Seeking Alpha

Lawrence Marc-Aurele

View as an RSS Feed
View Lawrence Marc-Aurele's Comments BY TICKER:
Latest  |  Highest rated
  • 3 Reasons To Buy Dendreon [View article]
    As long as Provenge is only available to advanced prostate cancer patients, it will remain a treatment of last resort, not a cure. If Provenge is not of great value to patients, it is of even less value to investors.
    Mar 24 11:49 AM | Likes Like |Link to Comment
  • Progenics Likely To Announce Positive Prostate Cancer Data In January [View article]
    Bottom line: Is it a cure?
    Jan 7 08:31 PM | 1 Like Like |Link to Comment
  • Wall Street Breakfast: Must-Know News [View article]
    @ James Carlini >Bob 123 -
    "You forget that the majority of people do NOT want Obamacare (the ones that will have to foot the bill) and that it is too awkward (as it stands now) to fund."

    Not wanting ObamaCare, which has already been passed, is not an excuse for republicans to hold America hostage to get its way. I did not want to get drafted, but when I got the 'letter', I showed up and did my job. Republicans are refusing to do theirs at the expense of veterans and basically all Americans.

    What needs to happen? Congress: Reopen the government and extend the debt limit without conditions--NOW. As for Obamacare, maybe it's not perfect, but it deserves a chance. If it's really no good it can always be repealed
    Oct 10 03:53 PM | 2 Likes Like |Link to Comment
  • European Committee Adopts Positive Opinion On Dendreon's Provenge [View article]
    They made bad decisions in only seeking advanced, metastatic, castrate resistant PCa patients. DNDN knew at the time--like everyone else--that it is better to take out the cancer at its earliest stage, yet they chose to only try Provenge on those at the latest stage.

    After looking at the information, it is clear that Dendreon only wanted the sickest patients. They bypassed all the men who could have been cured, and even to this day, still have the same idiotic inclusion/exclusion criteria. That's not a way to move forward.
    Aug 12 02:31 PM | 1 Like Like |Link to Comment
  • Has Dendreon's Window Of Opportunity Closed? [View article]
    @Joe Bill " I can tell you that Provenge works,"

    How do you know it works?
    Aug 12 02:14 PM | Likes Like |Link to Comment
  • European Committee Adopts Positive Opinion On Dendreon's Provenge [View article]
    When Dendreon ran clinical trials, they should not ever have required that participants be hormone refractory. Provenge might have had an actual cure instead of a theoretical 'survival benefit'.

    For this and perhaps other reasons, Dendreon has been the architect of its own demise--not to mention the demise of all who hoped for an alternative to standard, but harsh therapy.
    I speak from personal experience; they turned me away at a time when Provenge could have done the most good--for Dendreon, and for men like me.
    Aug 11 08:39 PM | 1 Like Like |Link to Comment
  • European Committee Adopts Positive Opinion On Dendreon's Provenge [View article]
    @ McBride-"There's a clear distinction, of course, between AIPC first line therapies and early prostate cancer"

    Yes, and that's exactly the problem, there should be no distinction. Cancer is cancer and patients who have it want it gone. A law should be passed that forbids clinical trials that require patients to be hormone refractory. Of course, ADT has a good place in the treatment of PCa, but current policy basically forces men to undergo ADT. That's not much of an option.
    Jul 1 02:19 PM | 1 Like Like |Link to Comment
  • European Committee Adopts Positive Opinion On Dendreon's Provenge [View article]
    @ Justice D-"For patients who come across this comment, there is an effective treatment before chemotherapy and more are coming in the near future"

    What is the name of this treatment? If it's only available to castrate resistant PCa patients, then it's too little, too late, like Provenge and all the rest. You certainly are not a fan of Provenge, that's your prerogative. Perhaps the patients you cite did poorly because Provenge was withheld until too late.

    But please, by all means, mention the name of the product you see as being superior to Provenge. My mind is open to it.
    Jun 30 08:33 PM | 1 Like Like |Link to Comment
  • European Committee Adopts Positive Opinion On Dendreon's Provenge [View article]
    " I understand how you feel, Lawrence,"
    It's more than 'how I feel'. Provenge is not a first line treatment for prostate cancer. Surgery is, same with chemo, radiation and hormone (ADT). These are all therapies that are first line. They are also therapies that most men would want to avoid.

    In order to try Provenge, a man must first try ADT, fail it, then he is 'eligible' for Provenge. Remember, Provenge is something I knew about before it was approved. It was my first and only choice of treatment, but was denied to me for the benefit of no one. Certainly others had the same denial.

    I wish you well also, Ted

    Jun 29 02:34 PM | Likes Like |Link to Comment
  • European Committee Adopts Positive Opinion On Dendreon's Provenge [View article]
    "Provenge is indicated for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated."

    From your first paragraph, these 'qualifiers' keeps Provenge from being a great product, and keeps it away from many patients, including me. Unfortunately, Provenge is not yet a first line treatment for prostate cancer.
    Jun 28 09:11 PM | Likes Like |Link to Comment
  • The Birth Of The Lithium Millionaires [View article]
    "The United States Patent and Trademark office has received so many patent applications for perpetual motion magnet motors they have closed the doors and don't even accept them anymore."

    The patent office does specifically state that 'non-useful' items 'such as' perpetual motion machines are not patentable. How could a working perpetual motion machine be 'non useful'? Or is it that no working PPM machines have been submitted? I'm guessing the latter, but then why would anyone try to patent something they know doesn't work?

    Great article, by the way!
    Jun 23 02:19 PM | 1 Like Like |Link to Comment
  • Peter Schiff Has It Totally Backwards - Gold Is Not Going 'To The Moon' [View article]
    "The problem Mr. Schiff has is that he blindly adheres to a false and outdated misunderstanding of modern monetary policy. Mr. Schiff follows the classic theory that printing money is inflationary, and that theory simply doesn't hold in all cases, and the current economic environment is one of those cases."

    So finding a way to maintain the 'current economic environment' is key here. If we can do that, the U.S. government can print as much money as it wants, nobody's money will lose buying power, we'll be debt free as a country, and everything will be just fine. That is good news indeed!
    Jun 13 04:38 PM | 1 Like Like |Link to Comment
  • Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
    @ KarinCA
    "Lawrence...If Kevetrin works in humans I don't share your concern there."

    If Kevetrin works in humans, or even has a chance of working in humans, it should not be tried on only terminal subjects. It should be tried as a first line treatment, something Provenge, Zytiga and others failed to do. If, as you say, 30 days of treatment and 30 days of followup yield positive results on terminal patients, think what the results might be on healthier patients.

    It is high time a biotech company has the guts to go for an out and out cure, as opposed to another 'therapy' or 'treatment'. That would be a catalyst to 'really move the stock'.
    May 24 01:45 PM | Likes Like |Link to Comment
  • Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived [View article]
    " The test subjects are terminal patients and the primary objectives of the trial are both safety and efficacy."

    If the only test subjects are terminal, Then Kevetrin is not available to prevent end stage disease, pretty much the downfall of Provenge. If there is hope for this or any other treatment, it would be in preventing PCa from ever getting to the point of being terminal. Treating patients while they are still healthy enough to benefit makes a lot more sense.
    May 16 01:56 PM | Likes Like |Link to Comment
  • Dendreon's Management Presents at Bank of America Merrill Lynch 2013 Health Care Conference (Transcript) [View article]
    "We showed some of the data as we looked at the quartile data breaking it down based on PSA. There is a lot of support based on what everybody has believed, which is the earlier, you use an immunotherapy, the greater the benefit." (quote from Mr. Schiffman's interview)

    Ken Oda's comment is right on the money. I've been asking these questions for over 4 years, trying to get Provenge for longer than that to no avail. Since Gregg Schiffman knows all about, 'the sooner, the better', Why has DNDN not sought FDA approval for PCa as a first-line treatment? Why not tap into the very large market of patients who have had no treatment, and will accept no other treatment than Provenge? Why is Provenge not available at the VA as an option?

    Of course, I'm assuming Mr. Schiffman would actually read any of the many SA comments. So, Mr. Schiffman, anyone else over there at Dendreon, why not answer Ken Oda's questions and mine?
    May 15 03:21 PM | Likes Like |Link to Comment